#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=4. Discussion
1-1	0-2	4.	_	_	_	_
1-2	3-13	Discussion	abstract	new	_	_

#Text=The main finding of our study is that the risk of AKI rose proportionally according to the amount of pRBC and FFP transfusions in both ABO-c and ABO-i LT , but this association of pRBC and FFP transfusions with post-transplant AKI was stronger in ABO-i LT than in ABO-c LT .
2-1	14-17	The	abstract[2]	new[2]	_	_
2-2	18-22	main	abstract[2]	new[2]	_	_
2-3	23-30	finding	abstract[2]	new[2]	_	_
2-4	31-33	of	abstract[2]	new[2]	_	_
2-5	34-37	our	abstract[2]|person|abstract[4]	new[2]|acc|new[4]	ana|coref|ana|coref	4-4|17-22[154_4]|4-4|17-22[154_4]
2-6	38-43	study	abstract[2]|abstract[4]	new[2]|new[4]	_	_
2-7	44-46	is	_	_	_	_
2-8	47-51	that	_	_	_	_
2-9	52-55	the	abstract[5]	new[5]	coref	7-18[0_5]
2-10	56-60	risk	abstract[5]	new[5]	_	_
2-11	61-63	of	abstract[5]	new[5]	_	_
2-12	64-67	AKI	abstract[5]|place	new[5]|new	coref	2-41
2-13	68-72	rose	_	_	_	_
2-14	73-87	proportionally	_	_	_	_
2-15	88-97	according	_	_	_	_
2-16	98-100	to	_	_	_	_
2-17	101-104	the	quantity[7]	new[7]	_	_
2-18	105-111	amount	quantity[7]	new[7]	_	_
2-19	112-114	of	quantity[7]	new[7]	_	_
2-20	115-119	pRBC	quantity[7]|abstract	new[7]|new	coref	2-35
2-21	120-123	and	_	_	_	_
2-22	124-127	FFP	substance|abstract[10]	new|new[10]	coref|coref|coref|coref	2-37|2-37[17_10]|2-37|2-37[17_10]
2-23	128-140	transfusions	abstract[10]	new[10]	_	_
2-24	141-143	in	abstract[10]	new[10]	_	_
2-25	144-148	both	abstract[10]|abstract[11]	new[10]|new[11]	coref	2-49[20_11]
2-26	149-154	ABO-c	abstract[10]|abstract[11]	new[10]|new[11]	_	_
2-27	155-158	and	abstract[10]	new[10]	_	_
2-28	159-164	ABO-i	abstract[10]|abstract	new[10]|new	coref	2-45[19_0]
2-29	165-167	LT	abstract[10]|abstract	new[10]|new	coref	3-25
2-30	168-169	,	_	_	_	_
2-31	170-173	but	_	_	_	_
2-32	174-178	this	abstract[14]	new[14]	_	_
2-33	179-190	association	abstract[14]	new[14]	_	_
2-34	191-193	of	abstract[14]	new[14]	_	_
2-35	194-198	pRBC	abstract[14]|abstract	new[14]|giv	coref	15-5
2-36	199-202	and	_	_	_	_
2-37	203-206	FFP	substance|abstract[17]	giv|giv[17]	coref|coref|coref|coref	3-32[32_17]|11-13|3-32[32_17]|11-13
2-38	207-219	transfusions	abstract[17]	giv[17]	_	_
2-39	220-224	with	abstract[17]	giv[17]	_	_
2-40	225-240	post-transplant	abstract[17]	giv[17]	_	_
2-41	241-244	AKI	abstract[17]|place	giv[17]|giv	coref	3-4
2-42	245-248	was	_	_	_	_
2-43	249-257	stronger	_	_	_	_
2-44	258-260	in	_	_	_	_
2-45	261-266	ABO-i	abstract[19]	giv[19]	coref	3-24[0_19]
2-46	267-269	LT	abstract[19]	giv[19]	_	_
2-47	270-274	than	_	_	_	_
2-48	275-277	in	_	_	_	_
2-49	278-283	ABO-c	abstract[20]	giv[20]	coref	5-16[46_20]
2-50	284-286	LT	abstract[20]	giv[20]	_	_
2-51	287-288	.	_	_	_	_

#Text=Given that the AKI rates increased in patients with preoperative anemia and that the influence of transfusion on AKI was more pronounced in ABO-i LT patients , any efforts to reduce perioperative transfusions may protect patients with ABO-i LT against AKI .
3-1	289-294	Given	_	_	_	_
3-2	295-299	that	_	_	_	_
3-3	300-303	the	abstract[22]	new[22]	_	_
3-4	304-307	AKI	place|abstract[22]	giv|new[22]	coref	3-19
3-5	308-313	rates	abstract[22]	new[22]	_	_
3-6	314-323	increased	_	_	_	_
3-7	324-326	in	_	_	_	_
3-8	327-335	patients	person[23]	new[23]	coref	3-24[30_23]
3-9	336-340	with	person[23]	new[23]	_	_
3-10	341-353	preoperative	person[23]|abstract[24]	new[23]|new[24]	_	_
3-11	354-360	anemia	person[23]|abstract[24]	new[23]|new[24]	_	_
3-12	361-364	and	_	_	_	_
3-13	365-369	that	_	_	_	_
3-14	370-373	the	abstract[25]	new[25]	_	_
3-15	374-383	influence	abstract[25]	new[25]	_	_
3-16	384-386	of	abstract[25]	new[25]	_	_
3-17	387-398	transfusion	abstract[25]|abstract	new[25]|new	coref	10-32[92_0]
3-18	399-401	on	abstract[25]	new[25]	_	_
3-19	402-405	AKI	abstract[25]|place	new[25]|giv	coref	3-41
3-20	406-409	was	_	_	_	_
3-21	410-414	more	_	_	_	_
3-22	415-425	pronounced	_	_	_	_
3-23	426-428	in	_	_	_	_
3-24	429-434	ABO-i	abstract|person[30]	giv|giv[30]	coref|coref|coref|coref	3-36[0_30]|3-38[34_0]|3-36[0_30]|3-38[34_0]
3-25	435-437	LT	abstract|person[30]	giv|giv[30]	coref	12-30
3-26	438-446	patients	person[30]	giv[30]	_	_
3-27	447-448	,	_	_	_	_
3-28	449-452	any	event[31]	new[31]	_	_
3-29	453-460	efforts	event[31]	new[31]	_	_
3-30	461-463	to	_	_	_	_
3-31	464-470	reduce	_	_	_	_
3-32	471-484	perioperative	abstract[32]	giv[32]	coref	12-32[117_32]
3-33	485-497	transfusions	abstract[32]	giv[32]	_	_
3-34	498-501	may	_	_	_	_
3-35	502-509	protect	_	_	_	_
3-36	510-518	patients	person	giv	coref	11-3[96_0]
3-37	519-523	with	_	_	_	_
3-38	524-529	ABO-i	abstract[34]	giv[34]	coref	5-7[45_34]
3-39	530-532	LT	abstract[34]	giv[34]	_	_
3-40	533-540	against	_	_	_	_
3-41	541-544	AKI	place	giv	coref	6-13
3-42	545-546	.	_	_	_	_

#Text=However , as our observations were from a retrospective analysis , prospective trials are required to confirm our hypothesis .
4-1	547-554	However	_	_	_	_
4-2	555-556	,	_	_	_	_
4-3	557-559	as	_	_	_	_
4-4	560-563	our	person|abstract[37]	giv|new[37]	ana|ana	4-18|4-18
4-5	564-576	observations	abstract[37]	new[37]	_	_
4-6	577-581	were	_	_	_	_
4-7	582-586	from	_	_	_	_
4-8	587-588	a	abstract[38]	new[38]	coref	20-8[170_38]
4-9	589-602	retrospective	abstract[38]	new[38]	_	_
4-10	603-611	analysis	abstract[38]	new[38]	_	_
4-11	612-613	,	_	_	_	_
4-12	614-625	prospective	event[39]	new[39]	_	_
4-13	626-632	trials	event[39]	new[39]	_	_
4-14	633-636	are	_	_	_	_
4-15	637-645	required	_	_	_	_
4-16	646-648	to	_	_	_	_
4-17	649-656	confirm	_	_	_	_
4-18	657-660	our	person|abstract[41]	giv|new[41]	ana|ana	17-22|17-22
4-19	661-671	hypothesis	abstract[41]	new[41]	_	_
4-20	672-673	.	_	_	_	_

#Text=Patient mortality and graft survival after ABO-i LT have been reported to be comparable to ABO-c LT , although there is still concern regarding the high incidence of antibody-mediated rejection , including biliary stricture related to a high isoagglutinin titer .
5-1	674-681	Patient	event[42]	new[42]	coref	7-7[0_42]
5-2	682-691	mortality	event[42]	new[42]	_	_
5-3	692-695	and	_	_	_	_
5-4	696-701	graft	abstract|event[44]	new|new[44]	coref|coref	7-4|7-4
5-5	702-710	survival	event[44]	new[44]	_	_
5-6	711-716	after	event[44]	new[44]	_	_
5-7	717-722	ABO-i	event[44]|abstract[45]	new[44]|giv[45]	coref	7-23[70_45]
5-8	723-725	LT	event[44]|abstract[45]	new[44]|giv[45]	_	_
5-9	726-730	have	_	_	_	_
5-10	731-735	been	_	_	_	_
5-11	736-744	reported	_	_	_	_
5-12	745-747	to	_	_	_	_
5-13	748-750	be	_	_	_	_
5-14	751-761	comparable	_	_	_	_
5-15	762-764	to	_	_	_	_
5-16	765-770	ABO-c	substance[46]	giv[46]	_	_
5-17	771-773	LT	substance[46]	giv[46]	_	_
5-18	774-775	,	_	_	_	_
5-19	776-784	although	_	_	_	_
5-20	785-790	there	_	_	_	_
5-21	791-793	is	_	_	_	_
5-22	794-799	still	abstract[47]	new[47]	_	_
5-23	800-807	concern	abstract[47]	new[47]	_	_
5-24	808-817	regarding	_	_	_	_
5-25	818-821	the	abstract[48]	new[48]	_	_
5-26	822-826	high	abstract[48]	new[48]	_	_
5-27	827-836	incidence	abstract[48]	new[48]	_	_
5-28	837-839	of	abstract[48]	new[48]	_	_
5-29	840-857	antibody-mediated	abstract[48]|abstract[49]	new[48]|new[49]	_	_
5-30	858-867	rejection	abstract[48]|abstract[49]	new[48]|new[49]	_	_
5-31	868-869	,	abstract[48]|abstract[49]	new[48]|new[49]	_	_
5-32	870-879	including	abstract[48]|abstract[49]	new[48]|new[49]	_	_
5-33	880-887	biliary	abstract[48]|abstract[49]|object|object[51]	new[48]|new[49]|new|new[51]	_	_
5-34	888-897	stricture	abstract[48]|abstract[49]|object[51]	new[48]|new[49]|new[51]	_	_
5-35	898-905	related	_	_	_	_
5-36	906-908	to	_	_	_	_
5-37	909-910	a	abstract[52]	new[52]	coref	6-1[54_52]
5-38	911-915	high	abstract[52]	new[52]	_	_
5-39	916-929	isoagglutinin	abstract[52]	new[52]	_	_
5-40	930-935	titer	abstract[52]	new[52]	_	_
5-41	936-937	.	_	_	_	_

#Text=This high isoagglutinin titer may provoke another major organ injury , including AKI , through an immunologic response .
6-1	938-942	This	abstract[54]	giv[54]	coref	8-16[75_54]
6-2	943-947	high	abstract[54]	giv[54]	_	_
6-3	948-961	isoagglutinin	person|abstract[54]	new|giv[54]	coref	8-18
6-4	962-967	titer	abstract[54]	giv[54]	_	_
6-5	968-971	may	_	_	_	_
6-6	972-979	provoke	_	_	_	_
6-7	980-987	another	event[56]	new[56]	coref	9-12[80_56]
6-8	988-993	major	event[56]	new[56]	_	_
6-9	994-999	organ	abstract|event[56]	new|new[56]	coref	9-9
6-10	1000-1006	injury	event[56]	new[56]	_	_
6-11	1007-1008	,	event[56]	new[56]	_	_
6-12	1009-1018	including	event[56]	new[56]	_	_
6-13	1019-1022	AKI	event[56]|place	new[56]|giv	coref	7-2
6-14	1023-1024	,	_	_	_	_
6-15	1025-1032	through	_	_	_	_
6-16	1033-1035	an	abstract[58]	new[58]	coref	15-11[133_58]
6-17	1036-1047	immunologic	abstract[58]	new[58]	_	_
6-18	1048-1056	response	abstract[58]	new[58]	_	_
6-19	1057-1058	.	_	_	_	_

#Text=As AKI affects graft outcomes and mortality after liver transplantation , it is important to elucidate modifiable risk factors of AKI in ABO-i LT .
7-1	1059-1061	As	_	_	_	_
7-2	1062-1065	AKI	place	giv	coref	7-21[69_0]
7-3	1066-1073	affects	_	_	_	_
7-4	1074-1079	graft	abstract|abstract[61]	giv|new[61]	_	_
7-5	1080-1088	outcomes	abstract[61]	new[61]	_	_
7-6	1089-1092	and	_	_	_	_
7-7	1093-1102	mortality	event	giv	_	_
7-8	1103-1108	after	_	_	_	_
7-9	1109-1114	liver	object|object[64]	new|new[64]	ana|coref|ana|coref	7-12[0_64]|12-16|7-12[0_64]|12-16
7-10	1115-1130	transplantation	object[64]	new[64]	_	_
7-11	1131-1132	,	_	_	_	_
7-12	1133-1135	it	object	giv	coref	10-23
7-13	1136-1138	is	_	_	_	_
7-14	1139-1148	important	_	_	_	_
7-15	1149-1151	to	person[66]	new[66]	_	_
7-16	1152-1161	elucidate	person[66]	new[66]	_	_
7-17	1162-1172	modifiable	person[66]|abstract[68]	new[66]|new[68]	coref	20-6[0_68]
7-18	1173-1177	risk	person[66]|abstract|abstract[68]	new[66]|giv|new[68]	coref	12-8
7-19	1178-1185	factors	person[66]|abstract[68]	new[66]|new[68]	_	_
7-20	1186-1188	of	person[66]|abstract[68]	new[66]|new[68]	_	_
7-21	1189-1192	AKI	person[66]|abstract[68]|place[69]	new[66]|new[68]|giv[69]	coref	8-4[0_69]
7-22	1193-1195	in	person[66]|abstract[68]|place[69]	new[66]|new[68]|giv[69]	_	_
7-23	1196-1201	ABO-i	person[66]|abstract[68]|place[69]|abstract[70]	new[66]|new[68]|giv[69]|giv[70]	coref	8-9[73_70]
7-24	1202-1204	LT	person[66]|abstract[68]|place[69]|abstract[70]	new[66]|new[68]|giv[69]|giv[70]	_	_
7-25	1205-1206	.	_	_	_	_

#Text=The reason why AKI occurs more frequently in ABO-i LT is not certain , although the high isoagglutinin titer may play a role .
8-1	1207-1210	The	abstract[71]	new[71]	_	_
8-2	1211-1217	reason	abstract[71]	new[71]	_	_
8-3	1218-1221	why	_	_	_	_
8-4	1222-1225	AKI	place	giv	coref	12-11[107_0]
8-5	1226-1232	occurs	_	_	_	_
8-6	1233-1237	more	_	_	_	_
8-7	1238-1248	frequently	_	_	_	_
8-8	1249-1251	in	_	_	_	_
8-9	1252-1257	ABO-i	abstract[73]	giv[73]	coref	11-5[97_73]
8-10	1258-1260	LT	abstract[73]	giv[73]	_	_
8-11	1261-1263	is	_	_	_	_
8-12	1264-1267	not	_	_	_	_
8-13	1268-1275	certain	_	_	_	_
8-14	1276-1277	,	_	_	_	_
8-15	1278-1286	although	_	_	_	_
8-16	1287-1290	the	abstract[75]	giv[75]	coref	9-1[77_75]
8-17	1291-1295	high	abstract[75]	giv[75]	_	_
8-18	1296-1309	isoagglutinin	person|abstract[75]	giv|giv[75]	_	_
8-19	1310-1315	titer	abstract[75]	giv[75]	_	_
8-20	1316-1319	may	_	_	_	_
8-21	1320-1324	play	_	_	_	_
8-22	1325-1326	a	abstract[76]	new[76]	_	_
8-23	1327-1331	role	abstract[76]	new[76]	_	_
8-24	1332-1333	.	_	_	_	_

#Text=A high isoagglutinin titer may lead to major organ damage through possible immunologic injury .
9-1	1334-1335	A	abstract[77]	giv[77]	coref	19-15[166_77]
9-2	1336-1340	high	abstract[77]	giv[77]	_	_
9-3	1341-1354	isoagglutinin	abstract[77]	giv[77]	_	_
9-4	1355-1360	titer	abstract[77]	giv[77]	_	_
9-5	1361-1364	may	_	_	_	_
9-6	1365-1369	lead	_	_	_	_
9-7	1370-1372	to	_	_	_	_
9-8	1373-1378	major	abstract[79]	new[79]	_	_
9-9	1379-1384	organ	object|abstract[79]	giv|new[79]	_	_
9-10	1385-1391	damage	abstract[79]	new[79]	_	_
9-11	1392-1399	through	_	_	_	_
9-12	1400-1408	possible	event[80]	giv[80]	_	_
9-13	1409-1420	immunologic	event[80]	giv[80]	_	_
9-14	1421-1427	injury	event[80]	giv[80]	_	_
9-15	1428-1429	.	_	_	_	_

#Text=In addition , the prevalent baseline metabolic alkalosis , low platelet count , and high incidence of mild arterial hypoxemia prior to transplantation surgery may contribute to the high incidence of intraoperative transfusion and low oxygen delivery to the kidney .
10-1	1430-1432	In	_	_	_	_
10-2	1433-1441	addition	_	_	_	_
10-3	1442-1443	,	_	_	_	_
10-4	1444-1447	the	abstract[83]	new[83]	_	_
10-5	1448-1457	prevalent	abstract[83]	new[83]	_	_
10-6	1458-1466	baseline	abstract|abstract[83]	new|new[83]	_	_
10-7	1467-1476	metabolic	person|abstract[83]	new|new[83]	_	_
10-8	1477-1486	alkalosis	abstract[83]	new[83]	_	_
10-9	1487-1488	,	_	_	_	_
10-10	1489-1492	low	abstract[85]	new[85]	_	_
10-11	1493-1501	platelet	object|abstract[85]	new|new[85]	_	_
10-12	1502-1507	count	abstract[85]	new[85]	_	_
10-13	1508-1509	,	_	_	_	_
10-14	1510-1513	and	_	_	_	_
10-15	1514-1518	high	abstract[86]	new[86]	_	_
10-16	1519-1528	incidence	abstract[86]	new[86]	_	_
10-17	1529-1531	of	abstract[86]	new[86]	_	_
10-18	1532-1536	mild	abstract[86]|abstract[88]	new[86]|new[88]	_	_
10-19	1537-1545	arterial	abstract[86]|substance|abstract[88]	new[86]|new|new[88]	_	_
10-20	1546-1555	hypoxemia	abstract[86]|abstract[88]	new[86]|new[88]	_	_
10-21	1556-1561	prior	abstract[86]	new[86]	_	_
10-22	1562-1564	to	abstract[86]	new[86]	_	_
10-23	1565-1580	transplantation	abstract[86]|object|event[90]	new[86]|giv|new[90]	coref|coref|coref|coref	11-20[0_90]|12-16[110_0]|11-20[0_90]|12-16[110_0]
10-24	1581-1588	surgery	abstract[86]|event[90]	new[86]|new[90]	_	_
10-25	1589-1592	may	_	_	_	_
10-26	1593-1603	contribute	_	_	_	_
10-27	1604-1606	to	_	_	_	_
10-28	1607-1610	the	abstract[91]	new[91]	_	_
10-29	1611-1615	high	abstract[91]	new[91]	_	_
10-30	1616-1625	incidence	abstract[91]	new[91]	_	_
10-31	1626-1628	of	abstract[91]	new[91]	_	_
10-32	1629-1643	intraoperative	abstract[91]|abstract[92]	new[91]|giv[92]	coref	11-13[100_92]
10-33	1644-1655	transfusion	abstract[91]|abstract[92]	new[91]|giv[92]	_	_
10-34	1656-1659	and	abstract[91]	new[91]	_	_
10-35	1660-1663	low	abstract[91]|abstract[94]	new[91]|new[94]	coref	16-21[143_94]
10-36	1664-1670	oxygen	abstract[91]|substance|abstract[94]	new[91]|new|new[94]	coref	16-22
10-37	1671-1679	delivery	abstract[91]|abstract[94]	new[91]|new[94]	_	_
10-38	1680-1682	to	abstract[91]|abstract[94]	new[91]|new[94]	_	_
10-39	1683-1686	the	abstract[91]|abstract[94]|object[95]	new[91]|new[94]|new[95]	_	_
10-40	1687-1693	kidney	abstract[91]|abstract[94]|object[95]	new[91]|new[94]|new[95]	_	_
10-41	1694-1695	.	_	_	_	_

#Text=Furthermore , patients with ABO-i LT already receive a substantial amount of FFP transfusion for plasma exchange prior to surgery .
11-1	1696-1707	Furthermore	_	_	_	_
11-2	1708-1709	,	_	_	_	_
11-3	1710-1718	patients	person[96]	giv[96]	coref	12-27[113_96]
11-4	1719-1723	with	person[96]	giv[96]	_	_
11-5	1724-1729	ABO-i	person[96]|abstract[97]	giv[96]|giv[97]	coref	12-29[0_97]
11-6	1730-1732	LT	person[96]|abstract[97]	giv[96]|giv[97]	_	_
11-7	1733-1740	already	_	_	_	_
11-8	1741-1748	receive	_	_	_	_
11-9	1749-1750	a	abstract[98]	new[98]	_	_
11-10	1751-1762	substantial	abstract[98]	new[98]	_	_
11-11	1763-1769	amount	abstract[98]	new[98]	_	_
11-12	1770-1772	of	abstract[98]	new[98]	_	_
11-13	1773-1776	FFP	abstract[98]|substance|abstract[100]	new[98]|giv|giv[100]	coref|coref|coref|coref	12-1|13-13[120_100]|12-1|13-13[120_100]
11-14	1777-1788	transfusion	abstract[98]|abstract[100]	new[98]|giv[100]	_	_
11-15	1789-1792	for	abstract[98]|abstract[100]	new[98]|giv[100]	_	_
11-16	1793-1799	plasma	abstract[98]|abstract[100]|object|event[102]	new[98]|giv[100]|new|new[102]	coref|coref|coref|coref	22-6|22-5[182_102]|22-6|22-5[182_102]
11-17	1800-1808	exchange	abstract[98]|abstract[100]|event[102]	new[98]|giv[100]|new[102]	_	_
11-18	1809-1814	prior	_	_	_	_
11-19	1815-1817	to	_	_	_	_
11-20	1818-1825	surgery	event	giv	coref	12-13[108_0]
11-21	1826-1827	.	_	_	_	_

#Text=FFP has been reported to be a risk factor for AKI after surgery , including liver transplantation , and the risk of AKI may increase when patients with ABO-i LT receive intraoperative FFP transfusions .
12-1	1828-1831	FFP	substance	giv	coref	12-33
12-2	1832-1835	has	_	_	_	_
12-3	1836-1840	been	_	_	_	_
12-4	1841-1849	reported	_	_	_	_
12-5	1850-1852	to	_	_	_	_
12-6	1853-1855	be	_	_	_	_
12-7	1856-1857	a	abstract[106]	new[106]	_	_
12-8	1858-1862	risk	abstract|abstract[106]	giv|new[106]	coref	12-20[111_0]
12-9	1863-1869	factor	abstract[106]	new[106]	_	_
12-10	1870-1873	for	abstract[106]	new[106]	_	_
12-11	1874-1877	AKI	abstract[106]|place[107]	new[106]|giv[107]	coref	12-23[0_107]
12-12	1878-1883	after	abstract[106]|place[107]	new[106]|giv[107]	_	_
12-13	1884-1891	surgery	abstract[106]|place[107]|event[108]	new[106]|giv[107]|giv[108]	coref	15-24[0_108]
12-14	1892-1893	,	abstract[106]|place[107]|event[108]	new[106]|giv[107]|giv[108]	_	_
12-15	1894-1903	including	abstract[106]|place[107]|event[108]	new[106]|giv[107]|giv[108]	_	_
12-16	1904-1909	liver	abstract[106]|place[107]|event[108]|object|object[110]	new[106]|giv[107]|giv[108]|giv|giv[110]	coref|coref|coref|coref	14-13|14-13[129_110]|14-13|14-13[129_110]
12-17	1910-1925	transplantation	abstract[106]|place[107]|event[108]|object[110]	new[106]|giv[107]|giv[108]|giv[110]	_	_
12-18	1926-1927	,	_	_	_	_
12-19	1928-1931	and	_	_	_	_
12-20	1932-1935	the	abstract[111]	giv[111]	coref	14-8[0_111]
12-21	1936-1940	risk	abstract[111]	giv[111]	_	_
12-22	1941-1943	of	abstract[111]	giv[111]	_	_
12-23	1944-1947	AKI	abstract[111]|place	giv[111]|giv	coref	14-11[127_0]
12-24	1948-1951	may	_	_	_	_
12-25	1952-1960	increase	_	_	_	_
12-26	1961-1965	when	_	_	_	_
12-27	1966-1974	patients	person[113]	giv[113]	coref	13-19[0_113]
12-28	1975-1979	with	person[113]	giv[113]	_	_
12-29	1980-1985	ABO-i	person[113]|abstract	giv[113]|giv	coref	18-11[157_0]
12-30	1986-1988	LT	person[113]|abstract	giv[113]|giv	_	_
12-31	1989-1996	receive	_	_	_	_
12-32	1997-2011	intraoperative	abstract[117]	giv[117]	_	_
12-33	2012-2015	FFP	substance|abstract[117]	giv|giv[117]	coref	13-13
12-34	2016-2028	transfusions	abstract[117]	giv[117]	_	_
12-35	2029-2030	.	_	_	_	_

#Text=Furthermore , an inflammatory , allergic , and immunologic reaction triggered by FFP transfusion may be exacerbated when patients receive additional intraoperative FFP .
13-1	2031-2042	Furthermore	_	_	_	_
13-2	2043-2044	,	_	_	_	_
13-3	2045-2047	an	abstract[118]	new[118]	_	_
13-4	2048-2060	inflammatory	abstract[118]	new[118]	_	_
13-5	2061-2062	,	abstract[118]	new[118]	_	_
13-6	2063-2071	allergic	abstract[118]	new[118]	_	_
13-7	2072-2073	,	abstract[118]	new[118]	_	_
13-8	2074-2077	and	abstract[118]	new[118]	_	_
13-9	2078-2089	immunologic	abstract[118]	new[118]	_	_
13-10	2090-2098	reaction	abstract[118]	new[118]	_	_
13-11	2099-2108	triggered	_	_	_	_
13-12	2109-2111	by	_	_	_	_
13-13	2112-2115	FFP	substance|abstract[120]	giv|giv[120]	coref|coref|coref|coref	13-21[122_0]|14-1[124_120]|13-21[122_0]|14-1[124_120]
13-14	2116-2127	transfusion	abstract[120]	giv[120]	_	_
13-15	2128-2131	may	_	_	_	_
13-16	2132-2134	be	_	_	_	_
13-17	2135-2146	exacerbated	_	_	_	_
13-18	2147-2151	when	_	_	_	_
13-19	2152-2160	patients	person	giv	coref	18-8[156_0]
13-20	2161-2168	receive	_	_	_	_
13-21	2169-2179	additional	substance[122]	giv[122]	coref	17-14[0_122]
13-22	2180-2194	intraoperative	substance[122]	giv[122]	_	_
13-23	2195-2198	FFP	substance[122]	giv[122]	_	_
13-24	2199-2200	.	_	_	_	_

#Text=Red cell transfusion is also a well-known risk factor of AKI after liver transplantation .
14-1	2201-2204	Red	abstract[124]	giv[124]	coref	14-6[126_124]
14-2	2205-2209	cell	place|abstract[124]	new|giv[124]	coref	21-5
14-3	2210-2221	transfusion	abstract[124]	giv[124]	_	_
14-4	2222-2224	is	_	_	_	_
14-5	2225-2229	also	_	_	_	_
14-6	2230-2231	a	abstract[126]	giv[126]	coref	15-5[132_126]
14-7	2232-2242	well-known	abstract[126]	giv[126]	_	_
14-8	2243-2247	risk	abstract|abstract[126]	giv|giv[126]	_	_
14-9	2248-2254	factor	abstract[126]	giv[126]	_	_
14-10	2255-2257	of	abstract[126]	giv[126]	_	_
14-11	2258-2261	AKI	abstract[126]|place[127]	giv[126]|giv[127]	coref	15-22[0_127]
14-12	2262-2267	after	abstract[126]|place[127]	giv[126]|giv[127]	_	_
14-13	2268-2273	liver	abstract[126]|place[127]|object|event[129]	giv[126]|giv[127]|giv|giv[129]	coref|coref|coref|coref	24-19|24-19[203_129]|24-19|24-19[203_129]
14-14	2274-2289	transplantation	abstract[126]|place[127]|event[129]	giv[126]|giv[127]|giv[129]	_	_
14-15	2290-2291	.	_	_	_	_

#Text=The negative effect of pRBC transfusion is multifaceted and includes a systemic inflammatory response , which contributes to the development of AKI after surgery .
15-1	2292-2295	The	abstract[130]	new[130]	_	_
15-2	2296-2304	negative	abstract[130]	new[130]	_	_
15-3	2305-2311	effect	abstract[130]	new[130]	_	_
15-4	2312-2314	of	abstract[130]	new[130]	_	_
15-5	2315-2319	pRBC	abstract[130]|substance|abstract[132]	new[130]|giv|giv[132]	coref|coref|coref|coref	16-5[0_132]|17-12|16-5[0_132]|17-12
15-6	2320-2331	transfusion	abstract[130]|abstract[132]	new[130]|giv[132]	_	_
15-7	2332-2334	is	_	_	_	_
15-8	2335-2347	multifaceted	_	_	_	_
15-9	2348-2351	and	_	_	_	_
15-10	2352-2360	includes	_	_	_	_
15-11	2361-2362	a	abstract[133]	giv[133]	coref	17-6[0_133]
15-12	2363-2371	systemic	abstract[133]	giv[133]	_	_
15-13	2372-2384	inflammatory	abstract[133]	giv[133]	_	_
15-14	2385-2393	response	abstract[133]	giv[133]	_	_
15-15	2394-2395	,	_	_	_	_
15-16	2396-2401	which	_	_	_	_
15-17	2402-2413	contributes	_	_	_	_
15-18	2414-2416	to	_	_	_	_
15-19	2417-2420	the	event[134]	new[134]	_	_
15-20	2421-2432	development	event[134]	new[134]	_	_
15-21	2433-2435	of	event[134]	new[134]	_	_
15-22	2436-2439	AKI	event[134]|place	new[134]|giv	coref	17-20[152_0]
15-23	2440-2445	after	event[134]	new[134]	_	_
15-24	2446-2453	surgery	event[134]|event	new[134]|giv	coref	26-5
15-25	2454-2455	.	_	_	_	_

#Text=A large amount of transfusion reflects excessive surgical bleeding , which leads to renal hypoperfusion and ischemia , resulting in poor oxygen delivery .
16-1	2456-2457	A	abstract[137]	new[137]	_	_
16-2	2458-2463	large	abstract[137]	new[137]	_	_
16-3	2464-2470	amount	abstract[137]	new[137]	_	_
16-4	2471-2473	of	abstract[137]	new[137]	_	_
16-5	2474-2485	transfusion	abstract[137]|abstract	new[137]|giv	coref	17-14[150_0]
16-6	2486-2494	reflects	_	_	_	_
16-7	2495-2504	excessive	abstract[139]	new[139]	_	_
16-8	2505-2513	surgical	abstract[139]	new[139]	_	_
16-9	2514-2522	bleeding	abstract[139]	new[139]	_	_
16-10	2523-2524	,	_	_	_	_
16-11	2525-2530	which	_	_	_	_
16-12	2531-2536	leads	_	_	_	_
16-13	2537-2539	to	_	_	_	_
16-14	2540-2545	renal	abstract[140]	new[140]	_	_
16-15	2546-2559	hypoperfusion	abstract[140]	new[140]	_	_
16-16	2560-2563	and	_	_	_	_
16-17	2564-2572	ischemia	abstract	new	_	_
16-18	2573-2574	,	_	_	_	_
16-19	2575-2584	resulting	_	_	_	_
16-20	2585-2587	in	_	_	_	_
16-21	2588-2592	poor	abstract[143]	giv[143]	_	_
16-22	2593-2599	oxygen	substance|abstract[143]	giv|giv[143]	coref	25-18
16-23	2600-2608	delivery	abstract[143]	giv[143]	_	_
16-24	2609-2610	.	_	_	_	_

#Text=There was a dose – response relationship between the amount of pRBC and FFP transfusion and the risk of AKI in our study .
17-1	2611-2616	There	_	_	_	_
17-2	2617-2620	was	_	_	_	_
17-3	2621-2622	a	quantity[144]	new[144]	coref	27-7[220_144]
17-4	2623-2627	dose	quantity[144]	new[144]	_	_
17-5	2628-2629	–	_	_	_	_
17-6	2630-2638	response	abstract|abstract[146]	giv|new[146]	_	_
17-7	2639-2651	relationship	abstract[146]	new[146]	_	_
17-8	2652-2659	between	abstract[146]	new[146]	_	_
17-9	2660-2663	the	abstract[146]|abstract[147]	new[146]|new[147]	coref	23-3[188_147]
17-10	2664-2670	amount	abstract[146]|abstract[147]	new[146]|new[147]	_	_
17-11	2671-2673	of	abstract[146]|abstract[147]	new[146]|new[147]	_	_
17-12	2674-2678	pRBC	abstract[146]|abstract[147]|object	new[146]|new[147]|giv	coref	18-21
17-13	2679-2682	and	abstract[146]|abstract[147]	new[146]|new[147]	_	_
17-14	2683-2686	FFP	abstract[146]|abstract[147]|substance|abstract[150]	new[146]|new[147]|giv|giv[150]	coref|coref|coref|coref	18-21[161_150]|21-11|18-21[161_150]|21-11
17-15	2687-2698	transfusion	abstract[146]|abstract[147]|abstract[150]	new[146]|new[147]|giv[150]	_	_
17-16	2699-2702	and	_	_	_	_
17-17	2703-2706	the	abstract[151]	new[151]	coref	31-2[0_151]
17-18	2707-2711	risk	abstract[151]	new[151]	_	_
17-19	2712-2714	of	abstract[151]	new[151]	_	_
17-20	2715-2718	AKI	abstract[151]|place[152]	new[151]|giv[152]	coref	27-28[226_152]
17-21	2719-2721	in	abstract[151]|place[152]	new[151]|giv[152]	_	_
17-22	2722-2725	our	abstract[151]|place[152]|person|abstract[154]	new[151]|giv[152]|giv|giv[154]	ana|coref|ana|coref	20-2|29-6[237_154]|20-2|29-6[237_154]
17-23	2726-2731	study	abstract[151]|place[152]|abstract[154]	new[151]|giv[152]|giv[154]	_	_
17-24	2732-2733	.	_	_	_	_

#Text=However , it is not clear why the patients undergoing ABO-i LT were more susceptible to the deleterious effects of pRBC transfusion .
18-1	2734-2741	However	_	_	_	_
18-2	2742-2743	,	_	_	_	_
18-3	2744-2746	it	abstract	new	cata	18-3[0_158]
18-4	2747-2749	is	_	_	_	_
18-5	2750-2753	not	_	_	_	_
18-6	2754-2759	clear	_	_	_	_
18-7	2760-2763	why	abstract[158]	new[158]	_	_
18-8	2764-2767	the	person[156]|abstract[158]	giv[156]|new[158]	_	_
18-9	2768-2776	patients	person[156]|abstract[158]	giv[156]|new[158]	_	_
18-10	2777-2787	undergoing	abstract[158]	new[158]	_	_
18-11	2788-2793	ABO-i	abstract[157]|abstract[158]	giv[157]|new[158]	coref	23-7[189_157]
18-12	2794-2796	LT	abstract[157]|abstract[158]	giv[157]|new[158]	_	_
18-13	2797-2801	were	abstract[158]	new[158]	_	_
18-14	2802-2806	more	abstract[158]	new[158]	_	_
18-15	2807-2818	susceptible	abstract[158]	new[158]	_	_
18-16	2819-2821	to	_	_	_	_
18-17	2822-2825	the	abstract[159]	new[159]	_	_
18-18	2826-2837	deleterious	abstract[159]	new[159]	_	_
18-19	2838-2845	effects	abstract[159]	new[159]	_	_
18-20	2846-2848	of	abstract[159]	new[159]	_	_
18-21	2849-2853	pRBC	abstract[159]|substance|abstract[161]	new[159]|giv|giv[161]	coref|coref|coref|coref	19-9|19-9[165_161]|19-9|19-9[165_161]
18-22	2854-2865	transfusion	abstract[159]|abstract[161]	new[159]|giv[161]	_	_
18-23	2866-2867	.	_	_	_	_

#Text=Possible mechanisms include that the adverse effect of pRBC transfusion may be aggravated by a high isoagglutinin titer .
19-1	2868-2876	Possible	abstract[162]	new[162]	_	_
19-2	2877-2887	mechanisms	abstract[162]	new[162]	_	_
19-3	2888-2895	include	_	_	_	_
19-4	2896-2900	that	_	_	_	_
19-5	2901-2904	the	event[163]	new[163]	_	_
19-6	2905-2912	adverse	event[163]	new[163]	_	_
19-7	2913-2919	effect	event[163]	new[163]	_	_
19-8	2920-2922	of	event[163]	new[163]	_	_
19-9	2923-2927	pRBC	event[163]|substance|abstract[165]	new[163]|giv|giv[165]	coref|coref|coref|coref	21-4[176_165]|22-15|21-4[176_165]|22-15
19-10	2928-2939	transfusion	event[163]|abstract[165]	new[163]|giv[165]	_	_
19-11	2940-2943	may	_	_	_	_
19-12	2944-2946	be	_	_	_	_
19-13	2947-2957	aggravated	_	_	_	_
19-14	2958-2960	by	_	_	_	_
19-15	2961-2962	a	abstract[166]	giv[166]	coref	20-17[172_166]
19-16	2963-2967	high	abstract[166]	giv[166]	_	_
19-17	2968-2981	isoagglutinin	abstract[166]	giv[166]	_	_
19-18	2982-2987	titer	abstract[166]	giv[166]	_	_
19-19	2988-2989	.	_	_	_	_

#Text=Although we accounted for confounding factors through propensity-score-matching and multivariable analysis , we could not adjust the isoagglutinin titer due to a lack of data .
20-1	2990-2998	Although	_	_	_	_
20-2	2999-3001	we	person	giv	ana	20-13
20-3	3002-3011	accounted	_	_	_	_
20-4	3012-3015	for	_	_	_	_
20-5	3016-3027	confounding	_	_	_	_
20-6	3028-3035	factors	abstract	giv	_	_
20-7	3036-3043	through	_	_	_	_
20-8	3044-3069	propensity-score-matching	abstract|abstract[170]	new|giv[170]	coref|coref	34-13[261_170]|34-13[261_170]
20-9	3070-3073	and	abstract[170]	giv[170]	_	_
20-10	3074-3087	multivariable	abstract[170]	giv[170]	_	_
20-11	3088-3096	analysis	abstract[170]	giv[170]	_	_
20-12	3097-3098	,	_	_	_	_
20-13	3099-3101	we	person	giv	ana	23-10
20-14	3102-3107	could	_	_	_	_
20-15	3108-3111	not	_	_	_	_
20-16	3112-3118	adjust	_	_	_	_
20-17	3119-3122	the	abstract[172]	giv[172]	_	_
20-18	3123-3136	isoagglutinin	abstract[172]	giv[172]	_	_
20-19	3137-3142	titer	abstract[172]	giv[172]	_	_
20-20	3143-3146	due	abstract[172]	giv[172]	_	_
20-21	3147-3149	to	_	_	_	_
20-22	3150-3151	a	quantity[173]	new[173]	_	_
20-23	3152-3156	lack	quantity[173]	new[173]	_	_
20-24	3157-3159	of	quantity[173]	new[173]	_	_
20-25	3160-3164	data	quantity[173]|abstract	new[173]|new	_	_
20-26	3165-3166	.	_	_	_	_

#Text=In addition , red cell transfusion is closely related to FFP transfusion .
21-1	3167-3169	In	_	_	_	_
21-2	3170-3178	addition	_	_	_	_
21-3	3179-3180	,	_	_	_	_
21-4	3181-3184	red	abstract[176]	giv[176]	coref	21-11[178_176]
21-5	3185-3189	cell	place|abstract[176]	giv|giv[176]	coref	26-2
21-6	3190-3201	transfusion	abstract[176]	giv[176]	_	_
21-7	3202-3204	is	_	_	_	_
21-8	3205-3212	closely	_	_	_	_
21-9	3213-3220	related	_	_	_	_
21-10	3221-3223	to	_	_	_	_
21-11	3224-3227	FFP	substance|abstract[178]	giv|giv[178]	coref|coref|coref|coref	22-2|22-1[180_178]|22-2|22-1[180_178]
21-12	3228-3239	transfusion	abstract[178]	giv[178]	_	_
21-13	3240-3241	.	_	_	_	_

#Text=Cumulative FFP transfusion after preoperative plasma exchange could be the leading cause , and pRBC transfusion could be a simple association .
22-1	3242-3252	Cumulative	abstract[180]	giv[180]	coref	22-15[185_180]
22-2	3253-3256	FFP	substance|abstract[180]	giv|giv[180]	_	_
22-3	3257-3268	transfusion	abstract[180]	giv[180]	_	_
22-4	3269-3274	after	_	_	_	_
22-5	3275-3287	preoperative	abstract[182]	giv[182]	coref	22-10[183_182]
22-6	3288-3294	plasma	substance|abstract[182]	giv|giv[182]	_	_
22-7	3295-3303	exchange	abstract[182]	giv[182]	_	_
22-8	3304-3309	could	_	_	_	_
22-9	3310-3312	be	_	_	_	_
22-10	3313-3316	the	abstract[183]	giv[183]	_	_
22-11	3317-3324	leading	abstract[183]	giv[183]	_	_
22-12	3325-3330	cause	abstract[183]	giv[183]	_	_
22-13	3331-3332	,	abstract[183]	giv[183]	_	_
22-14	3333-3336	and	abstract[183]	giv[183]	_	_
22-15	3337-3341	pRBC	abstract[183]|substance|abstract[185]	giv[183]|giv|giv[185]	coref|coref|coref|coref	22-19[186_185]|24-12|22-19[186_185]|24-12
22-16	3342-3353	transfusion	abstract[183]|abstract[185]	giv[183]|giv[185]	_	_
22-17	3354-3359	could	abstract[183]	giv[183]	_	_
22-18	3360-3362	be	abstract[183]	giv[183]	_	_
22-19	3363-3364	a	abstract[183]|abstract[186]	giv[183]|giv[186]	coref	23-4[0_186]
22-20	3365-3371	simple	abstract[183]|abstract[186]	giv[183]|giv[186]	_	_
22-21	3372-3383	association	abstract[183]|abstract[186]	giv[183]|giv[186]	_	_
22-22	3384-3385	.	_	_	_	_

#Text=To reduce the transfusion amount in ABO-i LT , we could adopt a restrictive transfusion policy by decreasing the transfusion threshold .
23-1	3386-3388	To	_	_	_	_
23-2	3389-3395	reduce	_	_	_	_
23-3	3396-3399	the	abstract[188]	giv[188]	coref	27-16[223_188]
23-4	3400-3411	transfusion	abstract|abstract[188]	giv|giv[188]	coref	23-15
23-5	3412-3418	amount	abstract[188]	giv[188]	_	_
23-6	3419-3421	in	_	_	_	_
23-7	3422-3427	ABO-i	abstract[189]	giv[189]	coref	30-6[242_189]
23-8	3428-3430	LT	abstract[189]	giv[189]	_	_
23-9	3431-3432	,	_	_	_	_
23-10	3433-3435	we	person	giv	ana	24-16
23-11	3436-3441	could	_	_	_	_
23-12	3442-3447	adopt	_	_	_	_
23-13	3448-3449	a	abstract[192]	new[192]	_	_
23-14	3450-3461	restrictive	abstract[192]	new[192]	_	_
23-15	3462-3473	transfusion	abstract|abstract[192]	giv|new[192]	coref	23-20
23-16	3474-3480	policy	abstract[192]	new[192]	_	_
23-17	3481-3483	by	_	_	_	_
23-18	3484-3494	decreasing	_	_	_	_
23-19	3495-3498	the	abstract[194]	new[194]	coref	24-11[199_194]
23-20	3499-3510	transfusion	abstract|abstract[194]	giv|new[194]	coref	24-8[196_0]
23-21	3511-3520	threshold	abstract[194]	new[194]	_	_
23-22	3521-3522	.	_	_	_	_

#Text=Although there is no established consensus regarding intraoperative transfusion , the pRBC transfusion threshold in our institution during liver transplantation was around 20 % in hematocrit .
24-1	3523-3531	Although	_	_	_	_
24-2	3532-3537	there	_	_	_	_
24-3	3538-3540	is	_	_	_	_
24-4	3541-3543	no	abstract[195]	new[195]	_	_
24-5	3544-3555	established	abstract[195]	new[195]	_	_
24-6	3556-3565	consensus	abstract[195]	new[195]	_	_
24-7	3566-3575	regarding	_	_	_	_
24-8	3576-3590	intraoperative	abstract[196]	giv[196]	coref	24-13[0_196]
24-9	3591-3602	transfusion	abstract[196]	giv[196]	_	_
24-10	3603-3604	,	_	_	_	_
24-11	3605-3608	the	abstract[199]	giv[199]	coref	24-22[204_199]
24-12	3609-3613	pRBC	abstract|abstract[199]	giv|giv[199]	_	_
24-13	3614-3625	transfusion	abstract|abstract[199]	giv|giv[199]	coref	26-1[213_0]
24-14	3626-3635	threshold	abstract[199]	giv[199]	_	_
24-15	3636-3638	in	abstract[199]	giv[199]	_	_
24-16	3639-3642	our	abstract[199]|person|organization[201]	giv[199]|giv|new[201]	ana|ana	29-6|29-6
24-17	3643-3654	institution	abstract[199]|organization[201]	giv[199]|new[201]	_	_
24-18	3655-3661	during	abstract[199]|organization[201]	giv[199]|new[201]	_	_
24-19	3662-3667	liver	abstract[199]|organization[201]|object|event[203]	giv[199]|new[201]|giv|giv[203]	_	_
24-20	3668-3683	transplantation	abstract[199]|organization[201]|event[203]	giv[199]|new[201]|giv[203]	_	_
24-21	3684-3687	was	_	_	_	_
24-22	3688-3694	around	abstract[204]	giv[204]	coref	25-1[206_204]
24-23	3695-3697	20	abstract[204]	giv[204]	_	_
24-24	3698-3699	%	abstract[204]	giv[204]	_	_
24-25	3700-3702	in	abstract[204]	giv[204]	_	_
24-26	3703-3713	hematocrit	abstract[204]|abstract	giv[204]|new	coref	26-12[215_0]
24-27	3714-3715	.	_	_	_	_

#Text=This threshold could be lowered further depending on the baseline status of recipients or the mixed venous oxygen concentrations .
25-1	3716-3720	This	abstract[206]	giv[206]	_	_
25-2	3721-3730	threshold	abstract[206]	giv[206]	_	_
25-3	3731-3736	could	_	_	_	_
25-4	3737-3739	be	_	_	_	_
25-5	3740-3747	lowered	_	_	_	_
25-6	3748-3755	further	_	_	_	_
25-7	3756-3765	depending	_	_	_	_
25-8	3766-3768	on	_	_	_	_
25-9	3769-3772	the	abstract[207]	new[207]	_	_
25-10	3773-3781	baseline	abstract[207]	new[207]	_	_
25-11	3782-3788	status	abstract[207]	new[207]	_	_
25-12	3789-3791	of	abstract[207]	new[207]	_	_
25-13	3792-3802	recipients	abstract[207]|person	new[207]|new	_	_
25-14	3803-3805	or	abstract[207]	new[207]	_	_
25-15	3806-3809	the	abstract[207]|animal[211]	new[207]|new[211]	_	_
25-16	3810-3815	mixed	abstract[207]|animal[211]	new[207]|new[211]	_	_
25-17	3816-3822	venous	abstract[207]|substance|animal[211]	new[207]|new|new[211]	_	_
25-18	3823-3829	oxygen	abstract[207]|substance|animal[211]	new[207]|giv|new[211]	_	_
25-19	3830-3844	concentrations	abstract[207]|animal[211]	new[207]|new[211]	_	_
25-20	3845-3846	.	_	_	_	_

#Text=Red cell transfusion during surgery could possibly be reduced by optimizing baseline hematocrit before surgery through the administration of erythropoietin .
26-1	3847-3850	Red	abstract[213]	giv[213]	coref	27-17[0_213]
26-2	3851-3855	cell	place|abstract[213]	giv|giv[213]	_	_
26-3	3856-3867	transfusion	abstract[213]	giv[213]	_	_
26-4	3868-3874	during	abstract[213]	giv[213]	_	_
26-5	3875-3882	surgery	abstract[213]|event	giv[213]|giv	coref	26-15
26-6	3883-3888	could	_	_	_	_
26-7	3889-3897	possibly	_	_	_	_
26-8	3898-3900	be	_	_	_	_
26-9	3901-3908	reduced	_	_	_	_
26-10	3909-3911	by	_	_	_	_
26-11	3912-3922	optimizing	_	_	_	_
26-12	3923-3931	baseline	abstract[215]	giv[215]	_	_
26-13	3932-3942	hematocrit	abstract[215]	giv[215]	_	_
26-14	3943-3949	before	_	_	_	_
26-15	3950-3957	surgery	event	giv	coref	27-20[224_0]
26-16	3958-3965	through	_	_	_	_
26-17	3966-3969	the	event[217]	new[217]	_	_
26-18	3970-3984	administration	event[217]	new[217]	_	_
26-19	3985-3987	of	event[217]	new[217]	_	_
26-20	3988-4002	erythropoietin	event[217]|substance	new[217]|new	coref	27-13
26-21	4003-4004	.	_	_	_	_

#Text=A previous randomized trial reported that a preoperative single intravenous dose of erythropoietin could reduce the transfusion amount during cardiac surgery , thereby reducing the incidence of postoperative AKI .
27-1	4005-4006	A	abstract[219]	new[219]	_	_
27-2	4007-4015	previous	abstract[219]	new[219]	_	_
27-3	4016-4026	randomized	abstract[219]	new[219]	_	_
27-4	4027-4032	trial	abstract[219]	new[219]	_	_
27-5	4033-4041	reported	_	_	_	_
27-6	4042-4046	that	_	_	_	_
27-7	4047-4048	a	quantity[220]	giv[220]	_	_
27-8	4049-4061	preoperative	quantity[220]	giv[220]	_	_
27-9	4062-4068	single	quantity[220]	giv[220]	_	_
27-10	4069-4080	intravenous	quantity[220]	giv[220]	_	_
27-11	4081-4085	dose	quantity[220]	giv[220]	_	_
27-12	4086-4088	of	quantity[220]	giv[220]	_	_
27-13	4089-4103	erythropoietin	quantity[220]|substance	giv[220]|giv	_	_
27-14	4104-4109	could	_	_	_	_
27-15	4110-4116	reduce	_	_	_	_
27-16	4117-4120	the	abstract[223]	giv[223]	_	_
27-17	4121-4132	transfusion	abstract|abstract[223]	giv|giv[223]	coref	28-6
27-18	4133-4139	amount	abstract[223]	giv[223]	_	_
27-19	4140-4146	during	abstract[223]	giv[223]	_	_
27-20	4147-4154	cardiac	abstract[223]|event[224]	giv[223]|giv[224]	_	_
27-21	4155-4162	surgery	abstract[223]|event[224]	giv[223]|giv[224]	_	_
27-22	4163-4164	,	_	_	_	_
27-23	4165-4172	thereby	_	_	_	_
27-24	4173-4181	reducing	_	_	_	_
27-25	4182-4185	the	abstract[225]	new[225]	_	_
27-26	4186-4195	incidence	abstract[225]	new[225]	_	_
27-27	4196-4198	of	abstract[225]	new[225]	_	_
27-28	4199-4212	postoperative	abstract[225]|place[226]	new[225]|giv[226]	coref	29-4[235_226]
27-29	4213-4216	AKI	abstract[225]|place[226]	new[225]|giv[226]	_	_
27-30	4217-4218	.	_	_	_	_

#Text=In addition , to reduce transfusion requirements , the intraoperative use of vasopressin was reported to reduce surgical bleeding through selective splanchnic vasoconstriction and by reducing portal blood flow .
28-1	4219-4221	In	_	_	_	_
28-2	4222-4230	addition	_	_	_	_
28-3	4231-4232	,	_	_	_	_
28-4	4233-4235	to	_	_	_	_
28-5	4236-4242	reduce	_	_	_	_
28-6	4243-4254	transfusion	abstract|abstract[228]	giv|new[228]	_	_
28-7	4255-4267	requirements	abstract[228]	new[228]	_	_
28-8	4268-4269	,	_	_	_	_
28-9	4270-4273	the	abstract[229]	new[229]	_	_
28-10	4274-4288	intraoperative	abstract[229]	new[229]	_	_
28-11	4289-4292	use	abstract[229]	new[229]	_	_
28-12	4293-4295	of	abstract[229]	new[229]	_	_
28-13	4296-4307	vasopressin	abstract[229]|substance	new[229]|new	_	_
28-14	4308-4311	was	_	_	_	_
28-15	4312-4320	reported	_	_	_	_
28-16	4321-4323	to	_	_	_	_
28-17	4324-4330	reduce	_	_	_	_
28-18	4331-4339	surgical	_	_	_	_
28-19	4340-4348	bleeding	_	_	_	_
28-20	4349-4356	through	_	_	_	_
28-21	4357-4366	selective	abstract[231]	new[231]	_	_
28-22	4367-4377	splanchnic	abstract[231]	new[231]	_	_
28-23	4378-4394	vasoconstriction	abstract[231]	new[231]	_	_
28-24	4395-4398	and	_	_	_	_
28-25	4399-4401	by	_	_	_	_
28-26	4402-4410	reducing	_	_	_	_
28-27	4411-4417	portal	abstract[233]	new[233]	_	_
28-28	4418-4423	blood	substance|abstract[233]	new|new[233]	_	_
28-29	4424-4428	flow	abstract[233]	new[233]	_	_
28-30	4429-4430	.	_	_	_	_

#Text=The incidence of AKI in our study was within the range reported in previous literature .
29-1	4431-4434	The	abstract[234]	new[234]	_	_
29-2	4435-4444	incidence	abstract[234]	new[234]	_	_
29-3	4445-4447	of	abstract[234]	new[234]	_	_
29-4	4448-4451	AKI	abstract[234]|place[235]	new[234]|giv[235]	coref	30-4[241_235]
29-5	4452-4454	in	abstract[234]|place[235]	new[234]|giv[235]	_	_
29-6	4455-4458	our	abstract[234]|place[235]|person|abstract[237]	new[234]|giv[235]|giv|giv[237]	coref|ana|coref|ana	30-12[243_237]|34-13|30-12[243_237]|34-13
29-7	4459-4464	study	abstract[234]|place[235]|abstract[237]	new[234]|giv[235]|giv[237]	_	_
29-8	4465-4468	was	_	_	_	_
29-9	4469-4475	within	_	_	_	_
29-10	4476-4479	the	abstract[238]	new[238]	_	_
29-11	4480-4485	range	abstract[238]	new[238]	_	_
29-12	4486-4494	reported	_	_	_	_
29-13	4495-4497	in	_	_	_	_
29-14	4498-4506	previous	abstract[239]	new[239]	coref	31-16[249_239]
29-15	4507-4517	literature	abstract[239]	new[239]	_	_
29-16	4518-4519	.	_	_	_	_

#Text=The incidence of AKI in ABO-i LT was also similar to a previous study .
30-1	4520-4523	The	abstract[240]	new[240]	_	_
30-2	4524-4533	incidence	abstract[240]	new[240]	_	_
30-3	4534-4536	of	abstract[240]	new[240]	_	_
30-4	4537-4540	AKI	abstract[240]|place[241]	new[240]|giv[241]	coref	31-5[0_241]
30-5	4541-4543	in	abstract[240]|place[241]	new[240]|giv[241]	_	_
30-6	4544-4549	ABO-i	abstract[240]|place[241]|abstract[242]	new[240]|giv[241]|giv[242]	coref	31-8[247_242]
30-7	4550-4552	LT	abstract[240]|place[241]|abstract[242]	new[240]|giv[241]|giv[242]	_	_
30-8	4553-4556	was	_	_	_	_
30-9	4557-4561	also	_	_	_	_
30-10	4562-4569	similar	_	_	_	_
30-11	4570-4572	to	_	_	_	_
30-12	4573-4574	a	abstract[243]	giv[243]	_	_
30-13	4575-4583	previous	abstract[243]	giv[243]	_	_
30-14	4584-4589	study	abstract[243]	giv[243]	_	_
30-15	4590-4591	.	_	_	_	_

#Text=The risk factors of AKI other than ABO-i LT were mostly consistent with those of the previous literature .
31-1	4592-4595	The	abstract[245]	new[245]	_	_
31-2	4596-4600	risk	abstract|abstract[245]	giv|new[245]	_	_
31-3	4601-4608	factors	abstract[245]	new[245]	_	_
31-4	4609-4611	of	abstract[245]	new[245]	_	_
31-5	4612-4615	AKI	abstract[245]|place	new[245]|giv	coref	32-9[252_0]
31-6	4616-4621	other	abstract[245]	new[245]	_	_
31-7	4622-4626	than	_	_	_	_
31-8	4627-4632	ABO-i	abstract[247]	giv[247]	ana	31-14[248_247]
31-9	4633-4635	LT	abstract[247]	giv[247]	_	_
31-10	4636-4640	were	_	_	_	_
31-11	4641-4647	mostly	_	_	_	_
31-12	4648-4658	consistent	_	_	_	_
31-13	4659-4663	with	_	_	_	_
31-14	4664-4669	those	abstract[248]	giv[248]	_	_
31-15	4670-4672	of	abstract[248]	giv[248]	_	_
31-16	4673-4676	the	abstract[248]|abstract[249]	giv[248]|giv[249]	_	_
31-17	4677-4685	previous	abstract[248]|abstract[249]	giv[248]|giv[249]	_	_
31-18	4686-4696	literature	abstract[248]|abstract[249]	giv[248]|giv[249]	_	_
31-19	4697-4698	.	_	_	_	_

#Text=The preoperative hemoglobin level was independently associated with post-transplant AKI .
32-1	4699-4702	The	abstract[251]	new[251]	_	_
32-2	4703-4715	preoperative	abstract[251]	new[251]	_	_
32-3	4716-4726	hemoglobin	place|abstract[251]	new|new[251]	_	_
32-4	4727-4732	level	abstract[251]	new[251]	_	_
32-5	4733-4736	was	_	_	_	_
32-6	4737-4750	independently	_	_	_	_
32-7	4751-4761	associated	_	_	_	_
32-8	4762-4766	with	_	_	_	_
32-9	4767-4782	post-transplant	place[252]	giv[252]	coref	33-13[0_252]
32-10	4783-4786	AKI	place[252]	giv[252]	_	_
32-11	4787-4788	.	_	_	_	_

#Text=The MELD score has been consistently reported to be a predictor of AKI .
33-1	4789-4792	The	abstract[254]	new[254]	_	_
33-2	4793-4797	MELD	abstract|abstract[254]	new|new[254]	_	_
33-3	4798-4803	score	abstract[254]	new[254]	_	_
33-4	4804-4807	has	_	_	_	_
33-5	4808-4812	been	_	_	_	_
33-6	4813-4825	consistently	_	_	_	_
33-7	4826-4834	reported	_	_	_	_
33-8	4835-4837	to	_	_	_	_
33-9	4838-4840	be	_	_	_	_
33-10	4841-4842	a	abstract[255]	new[255]	_	_
33-11	4843-4852	predictor	abstract[255]	new[255]	_	_
33-12	4853-4855	of	abstract[255]	new[255]	_	_
33-13	4856-4859	AKI	abstract[255]|place	new[255]|giv	coref	34-11[259_0]
33-14	4860-4861	.	_	_	_	_

#Text=Ischemic time was not identified as an independent predictor of AKI in our analysis , which could have been due to the relatively short ischemic time of LDLT .
34-1	4862-4870	Ischemic	abstract|time[258]	new|new[258]	coref|coref	34-25|34-25
34-2	4871-4875	time	time[258]	new[258]	_	_
34-3	4876-4879	was	_	_	_	_
34-4	4880-4883	not	_	_	_	_
34-5	4884-4894	identified	_	_	_	_
34-6	4895-4897	as	_	_	_	_
34-7	4898-4900	an	_	_	_	_
34-8	4901-4912	independent	_	_	_	_
34-9	4913-4922	predictor	_	_	_	_
34-10	4923-4925	of	_	_	_	_
34-11	4926-4929	AKI	place[259]	giv[259]	_	_
34-12	4930-4932	in	place[259]	giv[259]	_	_
34-13	4933-4936	our	place[259]|person|abstract[261]	giv[259]|giv|giv[261]	_	_
34-14	4937-4945	analysis	place[259]|abstract[261]	giv[259]|giv[261]	_	_
34-15	4946-4947	,	_	_	_	_
34-16	4948-4953	which	_	_	_	_
34-17	4954-4959	could	_	_	_	_
34-18	4960-4964	have	_	_	_	_
34-19	4965-4969	been	_	_	_	_
34-20	4970-4973	due	_	_	_	_
34-21	4974-4976	to	_	_	_	_
34-22	4977-4980	the	abstract[263]	new[263]	_	_
34-23	4981-4991	relatively	abstract[263]	new[263]	_	_
34-24	4992-4997	short	abstract[263]	new[263]	_	_
34-25	4998-5006	ischemic	abstract|abstract[263]	giv|new[263]	_	_
34-26	5007-5011	time	abstract[263]	new[263]	_	_
34-27	5012-5014	of	abstract[263]	new[263]	_	_
34-28	5015-5019	LDLT	abstract[263]|abstract	new[263]|new	_	_
34-29	5020-5021	.	_	_	_	_
